De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Guangdong Biolight Meditech Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jinyuan Yan

Algemeen directeur

CN¥1.8m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	13.8yrs
Eigendom CEO	27.0%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

Returns On Capital Signal Tricky Times Ahead For Guangdong Biolight Meditech (SZSE:300246)

Jun 07

Why Investors Shouldn't Be Surprised By Guangdong Biolight Meditech Co., Ltd.'s (SZSE:300246) 30% Share Price Plunge

Jun 06

There's No Escaping Guangdong Biolight Meditech Co., Ltd.'s (SZSE:300246) Muted Revenues Despite A 31% Share Price Rise

Mar 08

CEO

Jinyuan Yan (61 yo)

13.8yrs

Tenure

CN¥1,790,400

Compensatie

Mr. Jinyuan Yan has been a Director of Guangdong Biolight Meditech Co., Ltd since January 9, 2011 and serves as its Chairman and President.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jinyuan Yan	Chairman & President	13.8yrs	CN¥1.79m	27.03% CN¥ 539.5m
Jin Liang	VP & Director	10.8yrs	CN¥742.50k	0.058% CN¥ 1.1m
Wei Liao	VP & Director	1.8yrs	CN¥493.20k	0.0096% CN¥ 192.2k
Jundong Xue	Independent Director	3.3yrs	CN¥120.00k	geen gegevens
Zhen Xin Yang	Independent Director	1.8yrs	CN¥120.00k	geen gegevens
Dayuan Chen	Supervisor	9.4yrs	geen gegevens	geen gegevens
Daoguo Zhang	Supervisor	10.8yrs	geen gegevens	geen gegevens
Xiaoming Li	Director	4.4yrs	CN¥120.00k	geen gegevens
Bo Chen	Employee Supervisor	3.3yrs	geen gegevens	geen gegevens
Wenpu Tang	Non-Independent Director	1.8yrs	CN¥717.60k	geen gegevens
Maoliang Ran	Independent Director	1.8yrs	CN¥120.00k	geen gegevens
Jian Chen	Director	1.1yrs	CN¥30.00k	geen gegevens

3.3yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300246 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Guangdong Biolight Meditech Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Guangdong Biolight Meditech Co., Ltd., Annual General Meeting, May 20, 2024

Guangdong Biolight Meditech Co., Ltd. Approves Executive Elections

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New major risk - Revenue and earnings growth

Guangdong Biolight Meditech Co., Ltd. to Report Q3, 2024 Results on Oct 28, 2024

Less than half of directors are independent

Guangdong Biolight Meditech Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Returns On Capital Signal Tricky Times Ahead For Guangdong Biolight Meditech (SZSE:300246)

Why Investors Shouldn't Be Surprised By Guangdong Biolight Meditech Co., Ltd.'s (SZSE:300246) 30% Share Price Plunge

Guangdong Biolight Meditech Co., Ltd., Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: EPS: CN¥0.014 (vs CN¥0.10 in 1Q 2023)

Investor sentiment deteriorates as stock falls 20%

New minor risk - Share price stability

Guangdong Biolight Meditech Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

There's No Escaping Guangdong Biolight Meditech Co., Ltd.'s (SZSE:300246) Muted Revenues Despite A 31% Share Price Rise

Investor sentiment improves as stock rises 22%

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 18%

Guangdong Biolight Meditech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

Third quarter 2023 earnings released: EPS: CN¥0.02 (vs CN¥0.012 in 3Q 2022)

Guangdong Biolight Meditech Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.026 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.084 in 1Q 2022)

Guangdong Biolight Meditech Co., Ltd. Approves Executive Elections

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.018 (vs CN¥0.11 in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.039 loss per share (vs CN¥0.19 profit in 2Q 2021)

Guangdong Biolight Meditech Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 11 July 2022

Guangdong Biolight Meditech Co., Ltd. Approves 2021 Profit Distribution Plan

Guangdong Biolight Meditech Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.51 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥1.37 in 2Q 2020)

Guangdong Biolight Meditech Co., Ltd. Approves 2020 Profit Distribution Plan

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.28 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥2.37 (vs CN¥0.44 in FY 2019)

New 90-day low: CN¥25.16

New 90-day low: CN¥26.39

New 90-day low: CN¥26.84

New 90-day low: CN¥28.41

New 90-day low: CN¥31.40

Third quarter earnings released

Guangdong Biolight Meditech Co., Ltd. (SZSE:300246) signed an agreement to acquire 51% stake in Suzhou Jun Kang Medical Technology Co., Ltd. from Suzhou Dayisi Equity Investment Partnership (Limited Partnership) for approximately CNY 120 million.

First half earnings released

Guangdong Biolight Meditech Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd